Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation.
BACKGROUND
High-dose chemotherapy (HDT) followed by autologous stem-cell transplantation (ASCT) is considered the gold standard in the treatment of patients with relapsed or refractory Hodgkin's lymphoma (HL). However, the optimal salvage regimen has not yet been established.


METHODS
We retrospectively analyzed the efficacy and toxicity of MINE (mesna, ifosfamide, mitoxantrone, and etoposide) alternated with ESHAP (etoposide, methylprednisolone, high-dose cytarabine, and cisplatin) in the treatment of 61 relapsed or refractory HL patients after ABVD-based chemotherapy.


RESULTS
Overall, 25 patients (41%) achieved a complete response (CR), 23 (38%) a partial response (PR), 4 (7%) a stable disease, and 8 (13%) progressed for an overall response rate of 79%. Response to first-line chemotherapy was the most important prognostic factor for response to MINE-ESHAP (P = 0.041). No grade 4 extrahematologic toxic effects or toxic deaths were observed. Adequate peripheral blood stem-cell collection was achieved in 56 of 59 (95%) mobilized patients. Overall survival and event-free survival after HDT and ASCT were significantly higher for patients achieving CR/PR in comparison with those refractory to MINE-ESHAP (46% and 35% versus 74% and 69%, respectively).


CONCLUSIONS
MINE-ESHAP results in a high response rate with acceptable toxicity in patients with HL having failed ABVD-based treatment.
Fernández de Larrea
C
C
Department of Hematology.
Martínez
C
C
Department of Hematology. Electronic address: cmarti@clinic.ub.es.
Gaya
A
A
Department of Hematology.
López-Guillermo
A
A
Department of Hematology.
Rovira
M
M
Department of Hematology.
Fernández-Avilés
F
F
Department of Hematology.
Lozano
M
M
Department of Hemotherapy, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Bosch
F
F
Department of Hematology.
Esteve
J
J
Department of Hematology.
Nomdedeu
B
B
Department of Hematology.
Montserrat
E
E
Department of Hematology.
Carreras
E
E
Department of Hematology.
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D008935:Mitoguazone / Q000008:administration & dosage; D010507:Periodicity; D011241:Prednisone / Q000008:administration & dosage; D012008:Recurrence; D012189:Retrospective Studies; D016879:Salvage Therapy; D033581:Stem Cell Transplantation / Q000379:methods*; D014182:Transplantation, Autologous; D017211:Treatment Failure; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D055815:Young Adult
D003561:Cytarabine; D014747:Vinblastine; D005047:Etoposide; D008935:Mitoguazone; D002945:Cisplatin; D007069:Ifosfamide; D011241:Prednisone